Comparison of protective immune responses to apicomplexan parasites. by Frölich, S et al.
Hindawi Publishing Corporation
Journal of Parasitology Research
Volume 2012, Article ID 852591, 11 pages
doi:10.1155/2012/852591
Review Article
Comparison of Protective Immune Responses to
Apicomplexan Parasites
Sonja Fro¨lich,1 Rolf Entzeroth,2 and Michael Wallach1
1The ithree Institute, University of Technology Sydney, P.O. Box 123, Broadway, Sydney, NSW 2007, Australia
2 Institute of Zoology, Technical University Dresden, Mommsenstraße 13, 01062 Dresden, Germany
Correspondence should be addressed to Michael Wallach, michael.wallach@uts.edu.au
Received 9 May 2011; Accepted 27 June 2011
Academic Editor: Hugo D. Lujan
Copyright © 2012 Sonja Fro¨lich et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Members of the phylum Apicomplexa, which includes the species Plasmodium, Eimeria, Toxoplasma, and Babesia amongst others,
are the most successful intracellular pathogens known to humankind. The widespread acquisition of antimicrobial resistance to
most drugs used to date has sparked a great deal of research and commercial interest in the development of vaccines as alternative
control strategies. A few antigens from the asexual and sexual stages of apicomplexan development have been identified and their
genes characterised; however, the fine cellular and molecular details of the eﬀector mechanisms crucial for parasite inhibition and
stimulation of protective immunity are still not entirely understood. This paper provides an overview of what is currently known
about the protective immune response against the various types of apicomplexan parasites and focuses mainly on the similarities
of these pathogens and their host interaction. Finally, the evolutionary relationships of these parasites and their hosts, as well as
the modulation of immune functions that are critical in determining the outcome of the infection by these pathogenic organisms,
are discussed.
1. Introduction
Parasitic protozoans of the phylum Apicomplexa are
the most prevalent and successful pathogens known to
humankind. Today, half of the world’s population is at risk
of malaria caused by four Plasmodium species [1], and more
than 50 billion livestock reared for food production suﬀer
from debilitating intestinal diseases caused by many species
of Eimeria, Theileria, and Babesia, amongst others [2].
Eimeria is the cause of coccidiosis in chickens, a parasite that
infects the intestinal mucosa of the infected bird leading to
severe weight loss and even death of the host. Cryptosporid-
iosis is caused by Cryptosporidium species and, like Eimeria,
is transmitted by accidental ingestion of highly resistant and
environmentally stable oocysts that contaminate the food
and water. The disease is marked by self-limiting diarrhoea
in immunocompetent individuals, but in immunocompro-
mised patients, the disease can be fatal. Babesia is related
to the malaria parasite in that it infects the reticulocytes of
the infected cow and causes severe pathology and can cause
death as well. Toxoplasma is the cause of toxoplasmosis in
humans, a disease characterized bymild flu-like symptoms in
healthy hosts. However, immunocompromised individuals,
such as HIV/AIDS patients and organ transplant recipients,
often suﬀer from ocular toxoplasmosis or even encephalitis.
Theileria, an important cattle parasite transmitted by ticks, is
characterized by anaemia and high mortality rate especially
in pregnant cows.
Plasmodium infects red blood cells and is the cause of
malaria in humans as well as in several other vertebrate and
bird species. Nearly one million human deaths are attributed
to malaria each year, meaning that every 30 seconds a child
dies of this disease in Africa. This high toll in human and
animal life and wellbeing has been further exacerbated by
the inappropriate use of antimicrobial compounds over the
years. Thus, widespread resistance to most (if not all) drugs
used to date makes control of these parasites extremely
diﬃcult [3, 4]. The novel artemisinin-based therapies are
considered to be the new hope for malaria control and
have proved to be successful in interrupting the maturation
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of the infectious stages (oocysts) in the related parasite,
Eimeria, thereby reducing or blocking the transmission and
spread of the parasite [5–7]. However, there are fears that
overuse of these novel compounds will also facilitate the
selection of even more potent strains.
Over the past three decades, a number of putative
protective antigens from several members of the phylum has
attracted a great deal of research and commercial interest
in the hope to develop vaccines and alleviate the burden
on public health and world economy imposed by this class
of parasites [8–17]. The first antiprotozoan subunit vaccine
developed to date, CoxAbic, which contains antigens isolated
from the sexual stages of development of Eimeria is a
proof of principle for transmission-blocking immunity and
an example of a strategy that has been proved successful
in helping to tackle one of these important apicomplexan
diseases [18–21].
Despite the enormous eﬀorts to characterise the apicom-
plexan immunostimulatory antigens and genes encoding
them, the fine cellular and molecular details of the eﬀector
mechanisms crucial for parasite inhibition and stimulation
of protective immunity are still not fully understood. It is
hoped that unravelling the proteomes and genome sequences
of these protozoan pathogens will facilitate our understand-
ing of the mechanisms involved in the infectious process and
lead to the design of new eﬀective control strategies [22].
Early studies concerning the developmental biology and
immunology of the Apicomplexans have provided valuable
insights into the immune mechanisms responsible for the
inhibition of parasite growth and development and in the
establishment of host resistance to infection [23–27]. Eﬀorts
by research laboratories across the globe have demonstrated
that, in order to control the infection, both the innate
and adaptive arms of the immune system are crucial for
resistance and cross-protection [28]. This paper provides
an overview of Apicomplexan biology and focuses on the
protective immune response against the various types of api-
complexan parasites, from Eimeria to Plasmodium including
Toxoplasma, Cryptosporidium, Theileria, and Babesia. It also
addresses the evolutionary relationship of these parasites and
their hosts and the modulation of the host immune response
that are critical in determining the outcome of an infection.
2. Apicomplexan Life Cycle and
Parasite-Host Relationship
The apicomplexan life cycle includes both asexual multi-
plication (schizogony, merogony) and sexual reproduction
(gametogony) [25, 29, 30]. While some members of the
phylum require an intermediate host and a variety of
cell types to complete their developmental life cycle (i.e.,
Plasmodium, Babesia, Theileria, Toxoplasma), others lead a
monoxenous life style with the asexual and sexual stages
of development restricted to specific tissues of a single
host (i.e., Eimeria and Cryptosporidium species). Thus, the
possibility of culturing asexual stages in vitro [31], as well as
the feasibility of isolating relatively large numbers of sexual
forms (gametocytes), has granted Eimeria species a status of
an attractive and a relatively simple model for investigating
parasite-host interactions, as well as applying transmission-
blocking immunity [32].
Apicomplexan parasites aﬀect all classes of vertebrates,
including fish, amphibians, reptiles, birds andmammals. The
apparently long coevolutionary history of the apicomplexans
means that targeting the metabolic reactions and pathways
of the parasite also harms the host, making the identification
of therapeutic targets extremely diﬃcult. Recent advance-
ments in molecular biology have shed new light into the
coevolutionary history of the apicomplexa and their hosts.
This is based on the finding that the branching of the
evolutionary tree of at least some of these parasites coincided
with the evolution of the vertebrate host [33]. In addition,
it was found that several enzymes involved in a variety
of metabolic pathways are highly conserved between the
parasite and its host. Furthermore, comparative studies of
whole genome nucleotide sequences in several members of
the phylum have revealed that surface proteins, unlike the
house-keeping proteins and enzymes, have evolved rapidly
over the past 500 million years due to functional and
immune selective pressure [33]. This is especially evident in
the molecules comprising the apical complex, the invasion
machinery mediating physical recognition, cytoadherence,
and penetration of the host, which are parasite specific.
The successful invasion of the host cell by the apicom-
plexan parasite is dependent upon the sequential secre-
tion of proteins and other molecules from the rhoptries,
micronemes, and dense granules and results in the formation
of the parasitophorous vacuole (PV) (i.e., Toxoplasma,
Cryptosporidium, Plasmodium, and Eimeria spp.). This in
turn provides access to intracellular nutrients and protection
from the host’s immune system [34]. Although the PV shields
the parasite from the host defences, at the same time it
restricts access to nutrients in the host’s cytoplasm. Thus,
the Apicomplexa has adopted diﬀerent tactics to circumvent
this problem, including biochemical modification of the PV
making it permeable to essential nutrients. In contrast, some
parasites, such as Theileria spp., do not form the PV and
proliferate freely in the cytoplasm with direct access to host
nutrients [35].
Lateral gene transfer, best known for its role in antibiotic
resistance in bacteria, has been proposed as a mechanism
by which these opportunistic organisms acquire new genes
that confer parasite fitness [36–38]. For example, the
apical complex, actin-myosin-powered motor, evolved as
a result of the nuclear transfer of genes acquired during
the secondary endosymbiotic event. It is believed that
origin of the apicoplast can be attributed to endosymbiotic
partnership in which the plastid-containing eukaryote was
engulfed by a second eukaryotic cell. In addition, sexual
replication appears to be another contributing factor to the
diverse functions of the apicomplexan surface proteins and
the adaptations to genera-specific niches [39–41]. Therefore,
it is not surprising that Plasmodium and Babesia species
share evolutionarily conserved mechanisms of erythrocyte
invasion [23]. Moreover, transmembrane proteins (throm-
bospondin-related anonymous proteins—TRAP) bridging
the apical complex to the host cell in Plasmodium, Eimeria,
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and Toxoplasma also share a high degree of homology
[34, 42–44], suggesting that Apicomplexa use the same
molecular machinery to invade a wide variety of cells.
A great deal of research has also been carried out
to study the role of surface antigens in parasite growth,
development, and survival. Passive transfer of polyclonal
and monoclonal antibodies raised to asexual stage surface
antigens of T. gondii are capable of conferring resistance
against lethal challenge with this parasite [45, 46]. Similarly,
Eimeria and Plasmodium antisporozoite and antimerozoite
antibodies that recognize surface antigens, namely, glycosyl-
phosphatidylinositol- (GPI-) anchored antigens in E. tenella
(EtSAG1) and P. falciparum (MSP1), respectively, are able to
induce a strong inhibitory response and provide protection
against infection [47, 48]. In addition, the antigens found
on the surface of sporozoites have been implicated in the
recognition and invasion of the hepatocytes in malaria and,
therefore, represent promising targets for vaccine developers
[10, 42, 49, 50] (a detailed description of apicomplexan
invasion and egress has been reviewed recently by Westwood
and colleagues with a special emphasis on elements of the
apical complex and their potential role as vaccine targets
[51]). Thus, both asexual-stage surface proteins and the
molecules associated with the apical complex have been
proposed as potential candidates for vaccine development.
Another conserved feature of the phylum is the transmis-
sible, environmentally durable oocyst/cyst, the zygote stage
of the Coccidia (i.e., Toxoplasma, Eimeria, Cryptosporidium,
and Neospora species) [29, 52]. It is intriguing that asexual
reproduction in Eimeria is tightly regulated, and although
signals initiating the start of sexual reproduction have
not yet been identified, the 2nd, 3rd, and 4th generation
merozoites (depending upon which Eimeria species infects
the host chicken) diﬀerentiate into male (micro-) and
female (macro-) gametes in a synchronised manner. The
trademark of apicomplexan gametogenesis is the synthesis of
numerous lipid bodies and polysaccharide granules, believed
to be acquired from the host cell, serving as an energy
source for the developing zygote. Moreover, increased DNA
synthesis and RNA transcription to produce multinucleated
microgametocytes and heightened protein synthesis in the
macrogametocytes to produce wall forming bodies (WFBs)
are characteristics of sexual stage development at themolecu-
lar level [53–56]. Eimeria, Cryptosporidium, and Toxoplasma
spp. gametogenesis is completed by the formation of envi-
ronmentally resilient oocysts in the mucosae lining the gas-
trointestinal tract of chickens, humans, and cats, respectively.
The oocysts are then excreted with the faeces where they
mature (sporulate) becoming infectious. Cryptosporidium is
slightly diﬀerent from Eimeria and Toxoplasma in that the
Cryptosporidium oocysts can also release sporozoites in the
gut which are capable of infecting new epithelial cells (i.e.,
autoreinfection). In all three cases, transmission is primarily
by the accidental ingestion of sporulated oocysts.
Unlike the intestinal parasites described above, game-
togenesis of Plasmodium and Babesia spp. is completed
in the gut of their arthropod hosts. During development,
after fertilization of macrogametes by the microgametes and
invasion of the gut by the ookinete, the zygotes encase
themselves in a protective single-layered cyst wall to form
an oocyst. Flagellated sporozoites then exit the oocyst and
migrate from the midgut to the salivary gland of their
arthropod host. From there, they are injected into the blood
and subcutaneous tissue of the next vertebrate host the
arthropod bites.
3. Naturally Acquired Immunity to
Apicomplexan Parasites Is Exclusively
Dependent upon Cell-Mediated Immunity
Studies to elucidate the mechanism(s) of the protective
immune response to apicomplexan parasites have been
limited mainly due to the lack of being able to carry
out such studies in the definitive host such as cattle or
human beings. Thus, much of our understanding of the
protective immune response to apicomplexan infections has
been derived from murine models which can be genetically
modified [26, 57]. Generally speaking, parasite replication in
the host eventually leads to host cell lysis and parasite egress.
It is now widely accepted that cells of the innate immune
system and the molecules they produce and/or secrete are
important controlling factors of parasite infectivity and in
limiting the extent of parasitemia [58–61]. It is not clear
exactly how these molecules, particularly in the case of
parasites infecting host erythrocytes (i.e., Plasmodium and
Babesia spp.), interfere with parasite development.What does
appear to be the case is that this inhibition is accomplished
by the production of gamma interferon (IFN-γ), by natural
killer cells (NK), and tumour necrosis factor alpha (TNF-
α), nitric oxide (NO) and reactive oxygen species (ROS) by
macrophages [62–64]. Despite the fact that the mechanisms
by which IFN-γ mediates protection are not completely
understood, studies using IFN-γ and iNOS knock-out mice
infected with T. gondii indicated that activation of p47
guanosine triphosphatases (GTPases) leads to degradation of
the PV in infected cells [65].
While the immune response in healthy hosts is often
but not always able to control parasite replication and limit
the disease, immunocompromised individuals fail to stop
parasite growth, and clinical disease develops in nearly all
cases. This is especially evident in toxoplasmosis where
immunocompetent hosts control parasite replication causing
tachyzoites (the rapidly replicating asexual stages) to migrate
to muscle and brain tissues where they diﬀerentiate into
bradyzoite cysts (the slow-replicating form) and persist
throughout the host’s life. Although the tissue cysts can
become reactivated periodically, most healthy hosts never
develop clinical disease. In contrast, immunocompromised
patients, such as those suﬀering from AIDS, remain chron-
ically infected, whereby reactivation of the tissue cysts can
lead to toxoplasmic encephalitis with severe pathological
consequences.
The ability to clear acute and chronic infections with the
Apicomplexa seems to correlate with host CD4+ T-cell levels
[62, 66, 67]. Thus, studies involving athymic animals have
shown that T cells play a crucial role in the infectious process
[62, 68].
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The population of T cells coexpressing αβ markers
appears to be important for host defence against api-
complexan infections [69, 70]. Thus, it was demonstrated
that TCRα-deficient mice developed severe disease when
compared to controls [70]. Furthermore, mice lacking major
histocompatibility complex class II expression (i.e., CD4+ T-
cell deficient) appeared more susceptible to apicomplexan
infections [62, 67].
CD8+ T cells also appear to play a role in parasite growth
and dissemination because they provide sporozoite transport
from their initial infection site, as is the case for Eimeria
and Toxoplasma infections [69, 71]. During the course of
primary infection with Eimeria, CD8+ T cells appear to
play a role in parasite growth and dissemination because
they provide sporozoite transport from their initial infection
site to the crypt cells. On the other hand, reports have
also shown that increased numbers of CD8+ T cells in the
crypt epithelium act as cytotoxic killer cells facilitating the
clearance of the parasite-infected cells [72, 73]. Furthermore,
studies in infected chickens have shown that the contribution
of both CD4+ and CD8+ T-cell populations diﬀers according
to the infective species used [70]. Nevertheless, during avian
coccidiosis and babesiosis, CD4+ T-cell subsets were found
to be elevated in animals following challenge infections
[67, 70, 72]. An intriguing question arises from all of these
observations: why are some species or strains of parasites
extremely “immunogenic” and induce protective immunity,
while others seem to be invisible to the immune system?
Studies on naturally acquired immunity to malaria
have shown that adequate protective immunity to P. falci-
parum, the etiological agent of the most severe malaria in
humans, usually required repeated infections. Thus, protec-
tion against this particular strain appeared to be acquired
more slowly than against the less pathogenic P. vivax or
P. malariae [28]. Moreover, numerous studies have shown
that immunity appeared to be species specific and did
not confer protection against challenge with heterologous
species. However, it was reported that heavy exposure to
parasites induces the development of antigenic memory [74].
Although the molecular and cellular mechanisms driving the
onset of protective host immunity against malaria or any
other pathogenic protozoan are not entirely understood, it is
believed that susceptibility to infection is driven by extrinsic
factors such as antigenic variation and also by intrinsically
inappropriate immune responses [75]. This is particularly
evident in Theileria infections of immunocompromised
cattle, which often results in the death of the host animal. It
is theorised that the ability of Theileria to interfere with the
host’s apoptotic pathways is the crucial factor contributing to
mortality [35, 76]. Once inside the host cell, Theileria resides
free in the cytoplasm and induces uncontrolled proliferation
of the infected cell. Some have even compared Theileria
infections with cancer development and metastasis. Thus, it
appears that during Theileria infection the immune system
fails to control this proliferation in time, in turn resulting
in potent, nonspecific lysis of both infected and noninfected
cells.
Studies using immunocompetent animals have shown
that, in addition to innate host resistance, IFN-γ plays a key
role in the development of adaptive immunity and clearing
of Apicomplexa infections. For example, Cryptosporidium-
infected mice, with faulty IFN-γ gene expression, suﬀered
from severe mucosal destruction, and as a result they also
secreted more oocysts [60, 77]. Furthermore, mopping-up
the secreted IFN-γ by antibodies in immunocompromised
animals seemed to worsen C. parvum infection. In addition,
it is now widely accepted that IL-12, known to increase
host IFN-γ production, can reduce the severity and even
prevent infection by apicomplexan parasites [63]. Although
believed to be mediated by an IFN-γ-dependent mechanism,
the pathways or downstreammolecules crucial in this process
have not been well defined to date.
4. Masters of Disguise
Although viruses, which entirely depend on the host machin-
ery for replication and assembly of new viral particles, are
the experts in host cell manipulation, the Apicomplexa are
considered to be the masters of disguise. This is because they
have evolved to evade the host immune system to aid in their
own survival. Antigenic variation has been proposed as a key
factor in this process. Unlike allelic polymorphism, which
results in diﬀerent phenotypes or so-called parasite strains
[78], antigenic variation is the tightly regulated expression
of diﬀerent genes of a clonal population of parasites over
the natural course of infection [75]. Antigenic variation
amongst malarial and Babesia parasites is a prime example of
sophistication apicomplexans employed to avoid antibody-
mediated inhibition [79–81]. P. falciparum achieves this
by secreting a single type of a variant molecule (parasite-
derived erythrocyte membrane protein 1-PfEMP1) on the
surface of the infected erythrocyte at any one time. The
PfEMP1 surface proteins are encoded by a family of genes,
called var genes, and each individual parasite expresses
only a single var gene, keeping all other members of var
gene family in a transcriptionally silent state [82–84]. This
strategy in turn induces adhesion of the parasite-infected
erythrocytes to the blood vessels to avoid reaching the spleen,
whose main function is to rid the body of damaged and/or
infected blood cells. Similarly, sequestration of Babesia-
infected erythrocytes in the microvasculature enables the
Babesia to persist within the host maximizing its chances of
transmission [81]. This cytoadherence in Babesia is mediated
by constant gene conversion of ves family genes encoding the
variant erythrocyte surface antigen 1 (VESA1) [85].
A puzzling question arises from these observations: if
infected erythrocytes pass through the body unchecked
since they lack major histocompatibility complex (MHC)
expression, overwhelming proliferation of the parasites may
cause premature death of the host prior to successful
transmission to an arthropod vector? Interestingly, in spite
of the fact that malaria parasites sequentially express variant
surface molecules exposing the immunodominant antigens
to the host immune defences, infection is actually prolonged.
Thus, the parasite must undergo antigenic variation and
rates of growth that enable the host to control infection
while allowing for transmission of the parasite prior to
Journal of Parasitology Research 5
its death. This mechanism to prolong infection was also
evident in merozoites of Babesia species. Due to coating of
the merozoite surface with glycosyl-phosphatidyl-anchored
proteins crucial for initial attachment to the host erythrocyte
surface, they are targeted by host-protective antibodies
[86]. These surface-anchored proteins (Variable Merozoite
Surface Antigens-VMSA) exhibit varying degrees of intra-
species antigenic polymorphisms allowing these parasites
to evade the host immune system at the population level
[75]. Nevertheless, studies involving African children have
shown that variant specific immunity, namely, secretion of
IgG antibodies directed against P. falciparum variant surface
antigens (VSA), has been correlated with protection from
clinical malaria in Ghana, Kenya, and Tanzania [79, 87,
88]. Thus, VSA antigens have been proposed as excellent
candidates for malaria and Babesia vaccine development.
5. Humoral Immunity Protects against
Challenge Infections
Although B cells have been regarded as minor contributors
to protective immunity and resistance to primary infections
with Apicomplexa, numerous studies have shown that hosts
infected with these parasites are capable of producing
protective, parasite-specific immunoglobulins (Ig) of all
major classes after an episode of infection and recovery
[57, 89–92]. Thus, early work by Rose and colleagues has
shown that humoral antibodies, induced by live Eimeria
infection, can provide excellent passive protection against
challenge infections with the same parasite [93, 94]. Likewise,
studies on mice infected with T. gondii have shown that
intestinal IgA antibodies to major surface protein SAG-1
(P30) were produced after peroral infection and found to
inhibit infection of murine enterocytes by directly blocking
the parasite entry [91]. In addition, Precigout et al. have
demonstrated an inhibitory eﬀect of antibodies directed
against a 17-kDa merozoites membrane protein on B.
divergens parasite growth [92]. Furthermore, studies on
invasion of red blood cells by P. falciparum merozoites have
revealed that since RBCs do not express the MHC complex,
parasite killing by T lymphocytes is not important. Instead,
antibodies specific to merozoite surface molecules (MSP-1)
and proteins externalised from the apical complex play a
major role in immunity to asexual blood stages [95].
The Plasmodiummerozoite surface protein 1 (MSP-1) is a
200 kDamulticomponent precursor complex derived by pro-
teolytic processing during erythrocyte invasion. The 42 kDa
C-terminal component is cleaved (i.e., secondary processing)
to produce soluble 33 kDa and 19 kDa fragments that remain
on the merozoites surface [96]. Studies have shown that anti-
merozoite antibodies are capable of neutralizing parasites
by Fc-dependent mechanisms involving macrophages, thus
reducing the parasitemia and clinical disease [87, 97, 98].
In addition, a number of recent studies have shown that
children naturally infected with malaria secrete anti-MSP-
1 antibodies (MSP-119 mAb) that block the binding of
Plasmodium merozoites to the surface of the red blood cells
and also inhibit secondary processing of MSP-1. In addition,
studies investigating the protective properties of maternally
derived IgG and IgM antibodies to the 19 kDa domain
of MSP-1 of P. falciparum have shown that mothers who
have tested positive for anti-MSP-1 (19 kDa fragment) IgG
antibodies conferred protection against placental infection
and infection in their infants [99].
It has been shown that, in babesiosis infection, IgG
antibodies produced as a result of live infection can prevent
infection of erythrocytes by binding and neutralizing sporo-
zoites before they invade their target cells. Similar observa-
tions were reported in chickens where antisporozoite anti-
bodies specific to glycosyl-phosphatidylinositol-anchored
E. tenella surface antigen 1 (EtSAG1) appeared to inhibit
parasite binding and invasion of the host cell [24]. However,
it seems that the protective role of these antibodies is limited
since it can only neutralize sporozoites from the time the par-
asites egress and the time they gain access to new cells. Thus,
it is hoped that genome-wide fingerprinting techniques [100]
will aid in the identification of additional immunoprotective
antigens that can be used in combination to induce the
maximal inhibitory humoral immune response.
In addition to antigen-specific polyclonal and mon-
oclonal antibodies capable of inhibiting asexual stages,
antibodies raised to antigens localized exclusively to gameto-
cyte/zygote stages were also found to be highly immunogenic
and capable of providing passive protection in vivo [20,
101, 102]. Early experiments involving immunisation with
purified sexual-stage gametes of P. gallinaceum in chickens
showed that eﬀective transmission-blocking immunity can
be achieved by reducing the infectivity of gametocytes and
oocyst development [103, 104]. Thus, Pfs25 and Pvs25
proteins expressed on the surface of ookinetes in the
mosquito stage of P. falciparum and P. vivax have been used
extensively as candidates for malaria transmission-blocking
vaccines, since lowering the density of circulating parasites
would not produce sterilizing immunity, instead it would
allow individuals to develop long-lasting, naturally acquired
immunity to malaria [12, 105, 106].
Work by Wallach and coworkers, aimed at apply-
ing transmission-blocking immunity to control infections
caused by Eimeria, hypothesised that antibodies raised
against the gametocyte/zygote stages of development can
act to inhibit oocyst development and thereby provide a
block in parasite transmission (see Figure 1). A method
was developed for purifying E. maxima gametocytes from
the infected chicken gut mucosa and immunodominant
gametocyte antigens, namely, Emgam56, Emgam82, and
Emgam230 localized to the WFBs and the oocyst wall of
the maturing zygote, were extracted [53, 102, 108]. Passive
immunisation experiments showed that there was a good
correlation between the intensity of IgG and IgM antibodies
binding to gametocyte antigens by Western and ELISA with
the ability of those sera to provide passive protection in
vivo [109]. The mechanisms by which these antibodies
inhibit oocyst maturation are still obscure; however, it is
hypothesised that antibodies raised to the immunodominant
antigens retard zygote development by interfering with the
processing of wall proteins or the wall-hardening processes
[53, 110]. In addition, a protective monoclonal antibody
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Figure 1: Developing and mature micro- and macrogametes and
oocysts harvested from the infected chicken intestine 134 h post
infection (p.i.) and double-labelled with a monoclonal antibody
raised to antigens confound to WFB1s (E1D8) [107], and a poly-
clonal aﬃnity purified gametocyte antigens Emgam56, Emgam82,
and Emgam230, amongst other molecules (anti-APGA) specific to
molecules contained within the wall-forming bodies (1 and 2) [53]
and visualised with fluorescein isothiocyanate (green) or revealed
with rhodamine-conjugated goat anti-mouse IgG secondary anti-
body (red). Counterstained with DAPI. Abbreviations: N, nucleus;
SO, sporulated oocysts; SW, sporocyst wall; US, unsporulated
oocyst;WFB1, wall-forming body type 1;WFB2, wall-forming body
type 2. Bars represent 5 μm.
raised against Emgam56 localised to the WFB2 (1E11-11),
as well as the inner layer of the oocyst wall, was also found
to react strongly with the Stieda body of the sporulated
oocysts (M. Wallach, unpublished data). Similar results were
reported by Kru¨cken et al. using a monoclonal antibody
E2E5 raised to WFB2s of E. tenella [101]. The in vitro
excystation inhibition assay showed that the antibody E2E5
can significantly interfere with parasite development by
impairing sporozoite excystation. It is tempting to speculate
that the 1E11-11 monoclonal antibody inhibits or blocks
excystation of the sporocyst in a similar manner, thereby
reducing the number of infectious sporozoites released in
the intestine of infected birds allowing them to develop
protective immunity induced by exposure to low doses of
parasites.
Jenkins and colleagues have shown that ruminants
immunized with a DNA vaccine expressing a gene isolated
from C. parvum encoding a sporozoite antigen (CP 15/60)
were capable of inducing antigen-specific antibodies [111,
112]. In that study, it was found that using various routes
of vaccination resulted in diﬀering antibody responses and
titres. The authors, therefore, suggested that the route of
antigen delivery of any protozoan vaccine requires careful
formulation and optimisation of delivery systems.
Finally, in studies carried out by Wallach and co-
workers on Eimeria [109], it was found that in order to
achieve protective immunity using parasite extracts requires
the inclusion of the correct antigens and exclusion of the
irrelevant ones. Their results indicated that while some
parasite-specific antigens induce protective immunity, others
actually induce an exacerbation of the infection. Therefore,
in the design of any parasitic vaccine, it is crucial that the
combination of various antigens maximizes their inhibitory
eﬀect on parasite growth and development.
6. The Apicomplexa Are the Manipulators of
Host Defence Mechanisms
One of the main defence mechanisms employed by host cells
is programmed cell death (apoptosis) ensuring regulated
removal of damaged and infected cells [113]. But because
the survival and development of intracellular apicomplexan
parasites is dependent upon the continuous supply of host
cell nutrients and protection from immune attack, the par-
asites have adapted to extend the life of the infected cells by
inhibiting the host cell apoptotic machinery through inter-
ference with the intracellular signalling molecules, notably
phosphatidylinositol 3-kinase (PI3-K). PI3-K is involved in
a variety of functions including cell growth, proliferation,
and intracellular traﬃcking, amongst others [61, 114–117].
P. falciparum is a good example of how parasite secreted pro-
teins prevent host cell death to ensure its own development
and survival. Sporozoites of Plasmodium species are stealthy
invaders that first travel to the liver (hepatocyte) cells,
where the growth and development of the daughter cells,
hepatic merozoites, takes place. Recent results have shown
that prior to the establishment of the PV, sporozoites of P.
falciparum transmigrate through a number of hepatocytes
before they anchor to and invade the suitable cell via
exocytosis of proteins contained within the apical complex. It
has been shown that the thrombospondin-related adhesive-
protein- (TRAP-) like protein plays a role in this process.
Additionally, the wounding of the hepatocyte induced by
invading sporozoites releases growth factors which in turn
appear to inhibit PI3-K and block the signalling pathways
destined for apoptosis. Leiria˜o and colleagues have shown
that once the parasite is established in the hepatocyte, it
secretes HGF/MET signalling molecules into the host cell
cytoplasm, thereby conferring resistance to apoptosis to
ensure survival and maturation of the daughter cells [117].
However, which signalling upstream of PI3-K occurs during
Plasmodium infection is yet to be determined. Interestingly,
upon maturation of merozoites, Plasmodium seems to be
able to induce host cell death to liberate the motile progeny.
Strum et al. have shown that this process involves cysteine
proteases [49, 50]. Moreover, similar mechanisms were
found to play a role in release of sporozoites from the
oocysts [118]. Although work is ongoing to try and elucidate
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the mechanisms involved in these processes, it appears that
the Apicomplexa have learned to inhibit host cell death
during parasite development and subsequently activate it,
liberating thousands of new progeny.
T. gondii has also evolved a broad spectrum of adapta-
tions to challenges presented by its life style [119]. Chronic
toxoplasmosis is the trademark of the parasite’s success and
is induced by the slow-replicating bradyzoites safely tucked
away in the remodelled PV, the tissue cyst. Like Plasmodium,
T. gondiimodulates host cell apoptosis by both inhibiting and
triggering the programmed cell death [120]. Chen et al. have
shown that Fas/FasL ligand-dependent mechanisms mediate
the inflammatory responses induced by the apicomplexan
infection [115, 121]. But the parasites have evolved to neu-
tralize granzyme/perforin-mediated killing of infected T cells
and natural killer cells (NK) by modifying transcription and
posttranscriptional modification of IFN-γ -regulated genes,
the major mediators of resistance to T. gondii infections.
Likewise, del Cacho et al. have demonstrated that E. tenella
and E. necatrix second-generation schizonts first induce
NF-κβ activation to protect the transformed cells from
apoptosis, allowing the schizonts to mature and later cause
NF-κβ inhibition to trigger host cell apoptosis to facilitate
the release of merozoites [7].
The Apicomplexa have evolved to live in synergy with
their infected hosts because they completely depend on
it for survival; however, some apicomplexan infections
induce a great deal of immunopathology and can lead to
host cell death. For example, Eimeria and Cyclospora both
interfere with the absorption of nutrients across the intestinal
mucosa and can cause death due to malaise, diarrhoea, and
dehydration. Because apicomplexans increase in numbers
while, in their hosts, the severity of infection is proportional
to the parasite density—the smaller the number, the greater
the chance of asymptomatic infection and the greater the
chances of the parasite survival. However, the immunological
defence of a host can also cause extensive tissue damage
and clinical symptoms. Patients with cerebral malaria usually
have elevated levels of tumour necrosis factor alpha (TNF-
α) and IgE considered to be responsible for fever and tissue
lesions to an extent where vital functions of the host fail
leading to a coma [122].
7. Are We Losing the Battle against
Apicomplexan Parasites?
Despite a great deal of eﬀort and technological advancements
in biotechnology, molecular biology, genetics, immunology,
and vaccinology, there are no vaccines for humans against
malaria and toxoplasmosis at the present time, and it seems
that we are losing the battle in the fight against pathogenic
protozoans. The current failure to develop a practical vaccine
may well be attributed to our inadequate understanding
of the mechanisms underlying (1) the naturally acquired
immunity against apicomplexans, (2) acquired parasite
resistance to most (if not all) antimicrobial compounds
used to date, and (3) in the case of arthropod transmitted
protozoans, failure to implement adequate vector control
programs in tropical and subtropical regions.
The life cycles of the Apicomplexa are complex, thus, it is
hoped that a multivalent, multistage vaccine will alleviate the
problems caused by these pathogenic protozoans. Although
this approach has attracted a great deal of commercial
and research interest, the critical issues to be addressed
include the identification of stage-specific antigens capable
of inducing protective immunity and the delivery methods
in a form that will stimulate an adequate protective immune
response. The main impediment in the search and selection
for immunostimulatory antigens is the lack of in vitro assays
to analyse and predict immune responses. The transmission
blocking assays, relying on counting the number of oocysts
produced, and the inhibition of sporozoite invasion assays
have both been used extensively to evaluate parasite inhibi-
tion induced by neutralizing antibodies.
Although in vivo experimentation is extremely diﬃcult
for malaria, other model systems can be used to dissect the
fine details and the eﬀect of neutralizing antibodies. It is
very possible that, in the development of an antiprotozoan
vaccine capable of inducing only partial immunity, resistant
mutants would be selected that are even more pathogenic
than existing strains. In the malaria scenario, this could be
catastrophic since the parasite would undergo recycling and
be transmitted throughout the community leading to an
increase in morbidity and mortality. It is, therefore, of great
hope that in the battle against these pathogenic protozoan
parasites, including Plasmodium, Cryptosporidium, and Tox-
oplasma, the completion of their genomes and proteomes
may provide information needed to design vaccines, assess
the eﬀects of immunization on parasite pathogenicity and
the selection of unwanted mutants, and in the final analysis
control the diseases caused by this class of parasites.
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